分子診断市場規模、セグメント分析、2030年までの世界予測

この調査レポートでは、分子診断市場を製品とサービス（試薬とキット、機器、サービス）、検査の種類（ラボ検査とPoC検査）、サンプルの種類（血液、血清と血漿、尿、その他のサンプルの種類）、技術（ポリメラーゼ連鎖反応（PCR）、等温核酸増幅技術、in situ ハイブリダイゼーション、DNAシーケンシングと次世代シーケンシング（NGS）、DNAマイクロアレイ、その他の技術）、用途（感染症診断[肝炎（B型肝炎、C型肝炎、その他の肝炎疾患）、性感染症（HIV、CT/NG、HPV、梅毒、その他の性感染症）、呼吸器感染症（結核、インフルエンザ、咽頭炎、その他の呼吸器感染症）、院内感染、媒介性疾患、その他の感染症]、腫瘍学検査（乳がん、大腸がん、肺がん、前立腺がん、その他のがん）、遺伝子検査、その他のアプリケーション}、技術（マルチプレックス検査とシングルプレックス検査）、臨床アプリケーション（診断とスクリーニング）、エンドユーザー（病院や診療所、診断研究所、その他のエンドユーザー）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ）です。

本レポートは、分子診断市場の成長に影響を与える主要な要因（推進要因、制約要因、機会、課題など）に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、各社の事業概要、ソリューション、主要戦略、買収・契約に関する洞察を提供します。また、分子診断市場エコシステムにおける新興企業の競合分析も網羅しています。

本レポートは、市場リーダー企業や新規参入企業にとって、分子診断市場全体および各サブセグメントの収益数値の近似値に関する情報を提供するのに役立ちます。また、ステークホルダーが競争環境を理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供し、ステークホルダーが市場の動向を理解するのに役立ちます。

分子診断市場は、2025年に194億8,000万米ドルと推定され、予測期間中に9.6%のCAGRで成長し、2030年には307億4,000万米ドルに達すると予測されています。分子診断は、分子レベルおよび遺伝子レベルでの疾患検出を可能にすることで、現代の医療において重要な役割を果たしています。これらの技術は高い感度と特異性を提供し、病原体や遺伝子異常の早期発見を可能にします。処理時間の短縮、自動化プラットフォーム、アッセイ設計の改善など、継続的な技術進歩により、分子検査の信頼性とアクセス性が大幅に向上しています。これらの革新は、多様な医療現場における大規模な検査の取り組みを支援する上で重要です。さらに、インドなどの国では、政府および民間セクターのイニシアチブにより、国民の意識が高まり、診断および治療サービスへのアクセスが向上しています。このような取り組みにより、今後数年間で分子診断の採用が加速すると予想されます。

The molecular diagnostics market is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period. Molecular diagnostics plays a vital role in modern healthcare by enabling disease detection at the molecular and genetic level. These technologies offer high sensitivity and specificity, allowing for the early identification of pathogens and genetic abnormalities. Continuous technological advancements, such as faster processing times, automated platforms, and improved assay designs, have significantly enhanced the reliability and accessibility of molecular tests. These innovations are significant in supporting large-scale testing efforts across diverse healthcare settings. Moreover, in countries like India, government and private sector initiatives contribute to increased public awareness and greater access to diagnostic and treatment services. Such efforts are expected to accelerate the adoption of molecular diagnostics in the coming years.

“By sample type, the blood, serum, and plasma segment dominated the molecular diagnostics market  in 2024.”

By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share of the market in 2024. This is attributed to the high sensitivity and specificity these sample types offer in detecting a wide range of diseases, including viral infections and oncological conditions. Their stability during transportation and storage makes them ideal for centralized laboratories and point-of-care settings. Additionally, the growing adoption of personalized medicine and increased use of biomarkers in clinical decision-making fuel the demand for blood-based molecular testing. These advantages collectively position the segment for continued strong growth.

“By technology, the DNA sequencing & next-generation sequencing (NGS) segment is projected to achieve the highest growth during the forecast period.”

By technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & next-generation sequencing (NGS) segment is projected to witness the highest growth during the forecast period. This surge is driven by their expanding use in detecting genetic mutations, identifying infectious agents, and guiding personalized treatment plans. The increasing turnaround time and data accuracy improvements have also broadened their adoption in research and clinical settings. Moreover, NGS is gaining traction due to its high-throughput capabilities and utility in comprehensive genomic profiling. As precision medicine continues to advance, the demand for sequencing-based diagnostics is set to rise significantly.

“Asia Pacific is projected to be the fastest-growing regional market during the forecast period.”

The market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to witness the highest growth in the global molecular diagnostics market during the forecast period. This growth is supported by the rising healthcare investments, growing awareness of early disease detection, and increasing adoption of advanced diagnostic technologies across emerging economies. Countries such as China, India, and South Korea are experiencing rapid improvements in healthcare infrastructure and laboratory capacity. In addition, government initiatives aimed at strengthening infectious disease surveillance and expanding access to molecular testing are contributing to market growth. The large patient population and rising demand for personalized healthcare solutions further reinforce the region’s growth potential.

Break-up of primary participant profiles in the molecular diagnostics market:

• By Company Type: Tier 1 – 40%, Tier 2 –30%, and Tier 3 – 30%
• By Designation: C-level – 27%, Director-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa – 4%

The key players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott Laboratories (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), test type (lab tests and PoC tests),  sample type (blood, serum & plasma; urine; and other sample types), technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies), application {infectious disease diagnostics [hepatitis (hepatitis B, hepatitis C & other hepatitis diseases), sexually transmitted diseases (HIV, CT/NG, HPV, syphilis, & other sexually transmitted diseases), respiratory infectious diseases (tuberculosis, influenza, pharyngitis, & other respiratory infectious diseases), hospital-acquired infections, vector-borne diseases, and other infectious diseases], oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications}, technique (multiplex testing and singleplex testing),  clinical application (diagnostic and screening), end user (hospitals & clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A thorough analysis of the key industry players provides insights into their business overview, solutions, key strategies, acquisitions, and agreements. This report also covers a competitive analysis of upcoming startups in the molecular diagnostics market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report will help stakeholders understand the market pulse, providing information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers [Increasing prevalence of infectious diseases and cancer, growing R&D funding, surge in technological advancements in molecular diagnostics, and rising use of point-of-care (PoC) diagnostic tests], opportunities (Growing significance of companion diagnostics and increasing growth opportunities in emerging economies), restraints (Inadequate reimbursements and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape, operational barriers and labor shortage, and introduction of alternative technologies) influencing the growth of the molecular diagnostics market.
• Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the molecular diagnostics market
• Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US)

Table of Contents

1               INTRODUCTION              48

1.1           STUDY OBJECTIVES       48

1.2           MARKET DEFINITION   48

1.3           STUDY SCOPE   49

1.3.1        MARKET SEGMENTATION           49

1.3.2        REGIONAL SCOPE            50

1.4           INCLUSIONS & EXCLUSIONS       50

1.5           YEARS CONSIDERED      51

1.6           CURRENCY CONSIDERED            52

1.7           KEY STAKEHOLDERS     52

1.8           SUMMARY OF CHANGES               52

2               RESEARCH METHODOLOGY       53

2.1           RESEARCH DATA              53

2.1.1        SECONDARY DATA          53

2.1.1.1    Key secondary sources         54

2.1.1.2    Key data from secondary sources       54

2.1.2        PRIMARY DATA 55

2.1.2.1    Key primary sources             56

2.1.2.2    Key data from primary sources           56

2.1.2.3    Key industry insights           58

2.1.2.4    Breakdown of primary interviews      59

2.2           MARKET SIZE ESTIMATION         59

2.2.1        BOTTOM-UP APPROACH              60

2.2.1.1    Approach 1: Company revenue estimation approach     60

2.2.1.2    Approach 2: Presentation of companies and primary interviews                 60

2.2.1.3    Growth forecast    61

2.2.1.4    CAGR projections                 61

2.2.2        TOP-DOWN APPROACH                61

2.3           MARKET BREAKDOWN AND DATA TRIANGULATION                 63

2.4           MARKET SHARE ASSESSMENT   64

2.5           RESEARCH ASSUMPTIONS           64

2.5.1        PARAMETRIC ASSUMPTIONS     64

2.6           RESEARCH LIMITATIONS             64

2.7           RISK ASSESSMENT           65

3               EXECUTIVE SUMMARY  66

4               PREMIUM INSIGHTS       73

4.1           MOLECULAR DIAGNOSTICS MARKET OVERVIEW                 73

4.2           MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030   73

4.3           MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,  2025 VS. 2030       74

4.4           MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2025 VS. 2030       74

4.5           MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,  2025 VS. 2030    75

4.6           MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,  2025 VS. 2030       75

4.7           MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE,  2025 VS. 2030       76

4.8           MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030        76

4.9           MOLECULAR DIAGNOSTICS MARKET, BY END USER,  2025 VS. 2030       77

4.10         MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         77

5               MARKET OVERVIEW       78

5.1           INTRODUCTION              78

5.2           MARKET DYNAMICS       78

5.2.1        DRIVERS               79

5.2.1.1    Increasing prevalence of infectious diseases and cancer                 79

5.2.1.2    Growing R&D funding        81

5.2.1.3    Surge in technological advancements                82

5.2.1.4    Rising use of point-of-care diagnostic tests      83

5.2.2        RESTRAINTS      84

5.2.2.1    Inadequate reimbursements                84

5.2.2.2    High cost of molecular diagnostic instruments                84

5.2.3        OPPORTUNITIES              85

5.2.3.1    Growing significance of companion diagnostics              85

5.2.3.2    Increasing growth opportunities in emerging economies                 85

5.2.4        CHALLENGES    86

5.2.4.1    Changing regulatory landscape          86

5.2.4.2    Operational barriers and labor shortage           86

5.2.4.3    Introduction of alternative technologies           86

5.3           PRICING ANALYSIS          87

5.3.1        AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS             88

5.3.2        AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER              88

5.3.3        AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION   89

5.4           PATENT ANALYSIS          90

5.4.1        LIST OF MAJOR PATENTS             91

5.5           VALUE CHAIN ANALYSIS               91

5.6           SUPPLY CHAIN ANALYSIS             93

5.7           HS CODES           94

5.7.1        IMPORT SCENARIO (HS CODE 3822)        94

5.7.2        EXPORT SCENARIO (HS CODE 3822)        95

5.8           ECOSYSTEM ANALYSIS  96

5.9           PORTER’S FIVE FORCES ANALYSIS           97

5.9.1        THREAT FROM NEW ENTRANTS                98

5.9.2        THREAT FROM SUBSTITUTES   98

5.9.3        BARGAINING POWER OF BUYERS             98

5.9.4        BARGAINING POWER OF SUPPLIERS       98

5.9.5        INTENSITY OF COMPETITIVE RIVALRY 99

5.10         REGULATORY LANDSCAPE         99

5.10.1      REGULATORY FRAMEWORK       99

5.10.1.1  North America      99

5.10.1.1.1                US           99

5.10.1.1.2                Canada   99

5.10.1.2  Europe   99

5.10.1.2.1                Germany                 100

5.10.1.2.2                UK          100

5.10.1.2.3                France    101

5.10.1.2.4                Italy         101

5.10.1.3  Asia Pacific            101

5.10.1.3.1                China      101

5.10.1.3.2                Japan      101

5.10.1.3.3                India       102

5.10.1.4  Latin America       102

5.10.1.4.1                Brazil      102

5.10.1.4.2                Mexico   103

5.10.1.5  Middle East           103

5.10.1.5.1                Africa      103

5.10.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             103

5.11         TECHNOLOGY ANALYSIS             105

5.11.1      KEY TECHNOLOGIES     105

5.11.1.1  Polymerase chain reaction  105

5.11.2      COMPLEMENTARY TECHNOLOGIES       106

5.11.2.1  Microarrays            106

5.11.3      ADJACENT TECHNOLOGIES       107

5.11.3.1  Next-generation sequencing               107

5.12         KEY CONFERENCES & EVENTS, 2025–2026              107

5.13         TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            108

5.14         KEY STAKEHOLDERS AND BUYING CRITERIA     109

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           109

5.14.2      BUYING CRITERIA           110

5.15         INVESTMENT AND FUNDING SCENARIO               110

5.16         CASE STUDY ANALYSIS 111

5.16.1      CASE STUDY 1: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION                111

5.16.2      CASE STUDY 2: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS AND BED MANAGEMENT                 112

5.16.3      CASE STUDY 3: RAPID PCR TESTING STREAMLINED EMERGENCY CARE AND SURGICAL RESOURCE MANAGEMENT IN GERMAN HOSPITAL  112

5.17         IMPACT OF AI/GENERATIVE AI ON MOLECULAR DIAGNOSTICS MARKET 113

5.17.1      INTRODUCTION              113

5.17.2      MARKET POTENTIAL OF AI         113

5.17.2.1  Key use cases         114

5.17.3      IMPLEMENTATION OF AI BY KEY COMPANIES   114

5.17.4      FUTURE OF AI IN MOLECULAR DIAGNOSTICS MARKET                 115

5.18         US 2025 TARIFF 115

5.18.1      INTRODUCTION              115

5.18.2      KEY TARIFF RATES          116

5.18.3      PRICE IMPACT ANALYSIS             116

5.18.4      IMPACT ON REGION      117

5.18.4.1  North America      117

5.18.4.2  Europe   117

5.18.4.3  Asia Pacific            117

5.18.5      IMPACT ON END-USE INDUSTRIES          117

5.18.5.1  Hospitals & clinics                117

5.18.5.2  Diagnostic laboratories        118

6               MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE               119

6.1           INTRODUCTION              120

6.2           REAGENTS & KITS            120

6.2.1        INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION TO PROPEL MARKET            120

6.3           INSTRUMENTS 124

6.3.1        RISING NEED FOR QUICK AND ACCURATE TEST RESULTS TO BOOST MARKET    124

6.4           SERVICES & SOFTWARE 128

6.4.1        GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET 128

7               MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE                 131

7.1           INTRODUCTION              132

7.2           LAB TESTS          132

7.2.1        INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET   132

7.3           POC TESTS          136

7.3.1        INCREASED INVESTMENT BY PUBLIC HEALTH AGENCIES AND GOVERNMENTS TO BOOST MARKET     136

8               MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE                 140

8.1           INTRODUCTION              141

8.2           BLOOD, SERUM, AND PLASMA  141

8.2.1        INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET      141

8.3           URINE   145

8.3.1        NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET    145

8.4           OTHER SAMPLE TYPES 148

9               MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY  152

9.1           INTRODUCTION              153

9.2           POLYMERASE CHAIN REACTION               154

9.2.1        RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH             154

9.3           ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY  158

9.3.1        NEED FOR PROMPT DIAGNOSIS TO STIMULATE GROWTH             158

9.4           DNA SEQUENCING & NEXT-GENERATION SEQUENCING                 161

9.4.1        GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 161

9.5           IN SITU HYBRIDIZATION              165

9.5.1        RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES AND GENE MAPPING TO BOOST MARKET               165

9.6           DNA MICROARRAYS        168

9.6.1        SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET    168

9.7           OTHER TECHNOLOGIES               172

10            MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION                 176

10.1         INTRODUCTION              177

10.2         INFECTIOUS DISEASE DIAGNOSTICS      177

10.2.1      SEXUALLY TRANSMITTED DISEASES      181

10.2.1.1  CT/NG  185

10.2.1.1.1                Growing development of novel assays to boost market                 185

10.2.1.2  HIV         188

10.2.1.2.1                Increasing blood transfusions and blood donations to  propel market        188

10.2.1.3  HPV        191

10.2.1.3.1                Rising cases of cervical cancer to augment growth                 191

10.2.1.4  Syphilis  194

10.2.1.4.1                Growing demand for affordable and rapid molecular diagnostic solutions to drive market  194

10.2.1.5  Other sexually transmitted diseases  197

10.2.2      HEPATITIS          200

10.2.2.1  Hepatitis B             203

10.2.2.1.1                Need for ongoing management and monitoring of virus to drive market      203

10.2.2.2  Hepatitis C             206

10.2.2.2.1                Favorable government initiatives to support growth                 206

10.2.2.3  Other hepatitis diseases      209

10.2.3      RESPIRATORY INFECTIOUS DISEASES   212

10.2.3.1  Tuberculosis          216

10.2.3.1.1                Rising focus on reducing tuberculosis deaths to fuel market    216

10.2.3.2  Influenza                219

10.2.3.2.1                Growing strains and subtypes to drive market 219

10.2.3.3  Pharyngitis             222

10.2.3.3.1                Need to differentiate between bacterial and viral infections to fuel growth      222

10.2.3.4  Other respiratory infectious diseases                 225

10.2.4      HOSPITAL-ACQUIRED INFECTIONS        228

10.2.4.1  Booming geriatric population to aid growth    228

10.2.5      VECTOR-BORNE DISEASES          231

10.2.5.1  Growing focus on disease surveillance to propel market                 231

10.2.6      OTHER INFECTIOUS DISEASES 234

10.3         ONCOLOGY TESTING    238

10.3.1      BREAST CANCER              242

10.3.1.1  Increasing need to improve survival rates to support growth                 242

10.3.2      COLORECTAL CANCER 245

10.3.2.1  Rising demand for biomarkers to fuel market  245

10.3.3      LUNG CANCER  247

10.3.3.1  Increasing use of predictive biomarkers to drive market                 247

10.3.4      PROSTATE CANCER        250

10.3.4.1  Surge in advancements in genomic technologies to aid growth                 250

10.3.5      OTHER CANCER TYPES 253

10.4         GENETIC TESTING          256

10.4.1      GROWING IMPORTANCE OF DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET                 256

10.5         OTHER APPLICATIONS 259

11            MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE                 262

11.1         INTRODUCTION              263

11.2         MULTIPLEX TESTING    263

11.2.1      RISING DEMAND FOR QUICK DIAGNOSIS TO PROMOTE GROWTH             263

11.3         SINGLEPLEX TESTING   267

11.3.1      NEED FOR AFFORDABLE TESTING TO AUGMENT GROWTH             267

12            MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION   271

12.1         INTRODUCTION              272

12.2         DIAGNOSTIC     272

12.2.1      INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING AND TIMELY TREATMENT TO DRIVE MARKET                 272

12.3         SCREENING        275

12.3.1      GROWING IMPORTANCE OF EARLY INFECTIOUS DISEASE SCREENING TO PROPEL MARKET EXPANSION 275

13            MOLECULAR DIAGNOSTICS MARKET, BY END USER                 279

13.1         INTRODUCTION              280

13.2         DIAGNOSTIC LABORATORIES    280

13.2.1      INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH  280

13.3         HOSPITALS & CLINICS   283

13.3.1      GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH   283

13.4         OTHER END USERS         286

14            MOLECULAR DIAGNOSTICS MARKET, BY REGION                 290

14.1         INTRODUCTION              291

14.2         NORTH AMERICA             292

14.2.1      MACROECONOMIC OUTLOOK  299

14.2.2      US           300

14.2.2.1  Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market           300

14.2.3      CANADA               305

14.2.3.1  Growing focus on genomic research to fuel market        305

14.3         EUROPE               310

14.3.1      MACROECONOMIC OUTLOOK  311

14.3.2      GERMANY           316

14.3.2.1  Robust healthcare spending and increasing per capita disposable income to propel market     316

14.3.3      UK          321

14.3.3.1  Expanding community-based diagnostics to drive adoption of molecular diagnostics           321

14.3.4      FRANCE                327

14.3.4.1  Rising R&D expenditure for product launches and development of new technologies to augment growth            327

14.3.5      ITALY    332

14.3.5.1  Growing demographic shift toward elderly population to support market    332

14.3.6      SPAIN    337

14.3.6.1  Surge in demand for genetic and prenatal testing to aid growth                 337

14.3.7      RUSSIA 342

14.3.7.1  Increasing access to quality healthcare to boost market growth                 342

14.3.8      SWITZERLAND 347

14.3.8.1  Rising healthcare spending for new medications and therapies to drive market          347

14.3.9      REST OF EUROPE             352

14.4         ASIA PACIFIC     357

14.4.1      MACROECONOMIC OUTLOOK  359

14.4.2      CHINA  363

14.4.2.1  Growing public access to modern healthcare to drive market                 363

14.4.3      JAPAN   368

14.4.3.1  Universal healthcare reimbursement policy to support market                 368

14.4.4      INDIA    373

14.4.4.1  Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market         373

14.4.5      AUSTRALIA         378

14.4.5.1  Rising technological advancements to stimulate growth                 378

14.4.6      SOUTH KOREA  383

14.4.6.1  Favorable government initiatives for promoting medical tourism to support growth 383

14.4.7      REST OF ASIA PACIFIC   388

14.5         LATIN AMERICA                393

14.5.1      MACROECONOMIC OUTLOOK  394

14.5.2      BRAZIL 399

14.5.2.1  Universal healthcare access to drive adoption in Brazil 399

14.5.3      MEXICO                404

14.5.3.1  Booming medical tourism industry to aid growth            404

14.5.4      REST OF LATIN AMERICA             409

14.6         MIDDLE EAST & AFRICA                414

14.6.1      MACROECONOMIC OUTLOOK  415

14.6.2      SAUDI ARABIA  420

14.6.2.1  Rising government healthcare expenditure to boost market                 420

14.6.3      UAE        425

14.6.3.1  Improvements in healthcare infrastructure to support growth                 425

14.6.4      REST OF MIDDLE EAST & AFRICA             430

15            COMPETITIVE LANDSCAPE         436

15.1         INTRODUCTION              436

15.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            436

15.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET               436

15.3         REVENUE SHARE ANALYSIS         438

15.4         MARKET SHARE ANALYSIS, 2024                 439

15.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 441

15.5.1      STARS   441

15.5.2      EMERGING LEADERS     441

15.5.3      PERVASIVE PLAYERS      441

15.5.4      PARTICIPANTS 441

15.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         443

15.5.5.1  Company footprint               443

15.5.5.2  Region footprint   443

15.5.5.3  Product & service footprint 444

15.5.5.4  Sample type footprint           444

15.5.5.5  Application footprint            445

15.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        445

15.6.1      PROGRESSIVE COMPANIES         445

15.6.2      RESPONSIVE COMPANIES            445

15.6.3      DYNAMIC COMPANIES  446

15.6.4      STARTING BLOCKS         446

15.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 447

15.6.5.1  Detailed list of key startups/SMES   447

15.6.5.2  Competitive benchmarking of startups/SMES                447

15.7         COMPANY VALUATION & FINANCIAL METRICS 448

15.7.1      FINANCIAL METRICS      448

15.7.2      COMPANY VALUATION 449

15.8         BRAND/PRODUCT COMPARISON             450

15.9         COMPETITIVE SCENARIO             450

15.9.1      PRODUCT/SERVICES LAUNCHES AND APPROVALS                 450

15.9.2      DEALS  451

15.9.3      EXPANSIONS     452

16            COMPANY PROFILES      453

16.1         KEY PLAYERS     453

16.1.1      DANAHER CORPORATION           453

16.1.1.1  Business overview 453

16.1.1.2  Products/Services offered   454

16.1.1.3  Recent developments           456

16.1.1.3.1                Product/Service launches and approvals          456

16.1.1.3.2                Deals      457

16.1.1.3.3                Expansions             458

16.1.1.4  MnM view              458

16.1.1.4.1                Right to win           458

16.1.1.4.2                Strategic choices   458

16.1.1.4.3                Weaknesses and competitive threats 459

16.1.2      F. HOFFMANN-LA ROCHE LTD  460

16.1.2.1  Business overview 460

16.1.2.2  Products/Services offered   461

16.1.2.3  Recent developments           463

16.1.2.3.1                Product/Service launches and approvals          463

16.1.2.3.2                Deals      465

16.1.2.4  MnM view              466

16.1.2.4.1                Right to win           466

16.1.2.4.2                Strategic choices   466

16.1.2.4.3                Weaknesses and competitive threats 466

16.1.3      ILLUMINA, INC. 467

16.1.3.1  Business overview 467

16.1.3.2  Products/Services offered   468

16.1.3.3  Recent developments           469

16.1.3.3.1                Product/Service launches and approvals          469

16.1.3.3.2                Deals      470

16.1.3.3.3                Expansions             471

16.1.3.4  MnM view              471

16.1.3.4.1                Right to win           471

16.1.3.4.2                Strategic choices   472

16.1.3.4.3                Weaknesses and competitive threats 472

16.1.4      HOLOGIC, INC. 473

16.1.4.1  Business overview 473

16.1.4.2  Products/Services offered   474

16.1.4.3  Recent developments           475

16.1.4.3.1                Product/Service launches and approvals          475

16.1.4.3.2                Deals      476

16.1.4.4  MnM view              477

16.1.4.4.1                Right to win           477

16.1.4.4.2                Strategic choices   477

16.1.4.4.3                Weaknesses and competitive threats 477

16.1.5      BIOMÉRIEUX     478

16.1.5.1  Business overview 478

16.1.5.2  Products/Services offered   479

16.1.5.3  Recent developments           481

16.1.5.3.1                Product/Service launches and approvals          481

16.1.5.3.2                Deals      482

16.1.5.4  MnM view              483

16.1.5.4.1                Right to win           483

16.1.5.4.2                Strategic choices   483

16.1.5.4.3                Weaknesses and competitive threats 483

16.1.6      ABBOTT LABORATORIES             484

16.1.6.1  Business overview 484

16.1.6.2  Products/Services offered   485

16.1.6.3  Recent developments           487

16.1.6.3.1                Product/Service launches and approvals          487

16.1.6.3.2                Deals      488

16.1.7      THERMO FISHER SCIENTIFIC INC.            489

16.1.7.1  Business overview 489

16.1.7.2  Products/Services offered   490

16.1.7.3  Recent developments           491

16.1.7.3.1                Product/Service launches and approvals          491

16.1.7.3.2                Deals      492

16.1.8      QIAGEN N.V.      493

16.1.8.1  Business overview 493

16.1.8.2  Products/Services offered   494

16.1.8.3  Recent developments           496

16.1.8.3.1                Product/Service launches and approvals          496

16.1.8.3.2                Deals      498

16.1.8.3.3                Expansions             499

16.1.9      REVVITY, INC.   500

16.1.9.1  Business overview 500

16.1.9.2  Products/Services offered   501

16.1.10   MYRIAD GENETICS, INC.               502

16.1.10.1                 Business overview 502

16.1.10.2                 Products/Services offered   503

16.1.10.3                 Recent developments           504

16.1.10.3.1             Product/Service launches and approvals          504

16.1.10.3.2             Deals      504

16.1.11   SIEMENS HEALTHINEERS AG      507

16.1.11.1                 Business overview 507

16.1.11.2                 Products/Services offered   508

16.1.11.3                 Recent developments           509

16.1.11.3.1             Product/Service launches and approvals          509

16.1.11.3.2             Deals      509

16.1.11.3.3             Expansions             510

16.2         OTHER PLAYERS              511

16.2.1      BECTON, DICKINSON AND COMPANY (BD)         511

16.2.2      GRIFOLS, S.A.     512

16.2.3      QUIDELORTHO CORPORATION                513

16.2.4      DIASORIN S.P.A.                514

16.2.5      EXACT SCIENCES CORPORATION             516

16.2.6      GENETIC SIGNATURES 517

16.2.7      AGILENT TECHNOLOGIES, INC.                518

16.2.8      MDXHEALTH     519

16.2.9      BIOCARTIS          520

16.2.10   MEDIGEN BIOTECHNOLOGY CORP.        521

16.2.11   VELA DIAGNOSTICS       522

16.2.12   AMOY DIAGNOSTICS CO., LTD. 523

16.2.13   BRUKER CORPORATION (ELITECHGROUP)         524

16.2.14   MOLBIO DIAGNOSTICS LIMITED              526

16.2.15   GENEOMBIOTECHNOLOGIES   527

16.2.16   SAVYON DIAGNOSTICS 528

16.2.17   UNIOGEN OY     529

17            APPENDIX           530

17.1         DISCUSSION GUIDE        530

17.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                536

17.3         CUSTOMIZATION OPTIONS        538

17.4         RELATED REPORTS         538

17.5         AUTHOR DETAILS           539

LIST OF TABLES

TABLE 1                MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES               56

TABLE 2                MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 65

TABLE 3                TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045        81

TABLE 4                NUMBER OF CANCER PATIENTS WORLDWIDE, BY REGION,

2022 VS. 2035 VS. 2045      81

TABLE 5                AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS,

2023–2025 (USD)                88

TABLE 6                AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER, 2023–2025 (USD)                88

TABLE 7                AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS,

BY REGION, 2023–2025 (USD)      89

TABLE 8                LIST OF MAJOR PATENTS, 2022–2024        91

TABLE 9                IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,

2020–2024 (USD MILLION)            95

TABLE 10              EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,

2020–2024 (USD MILLION)            95

TABLE 11              MOLECULAR DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM       96

TABLE 12              IMPACT OF PORTER’S FORCES ON MOLECULAR DIAGNOSTICS MARKET 98

TABLE 13              CLASSIFICATION OF IVD DEVICES IN EUROPE                 100

TABLE 14              TIME, COST, AND COMPLEXITY OF DEVICE REGISTRATION PROCESS IN JAPAN         102

TABLE 15              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 104

TABLE 16              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           104

TABLE 17              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 104

TABLE 18              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 105

TABLE 19              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 105

TABLE 20              MOLECULAR DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026       108

TABLE 21              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,

BY PRODUCT & SERVICE (%)      110

TABLE 22              KEY BUYING CRITERIA, BY PRODUCT & SERVICE                 110

TABLE 23              RECIPROCAL TARIFF RATES ADJUSTED BY US                 116

TABLE 24              MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            120

TABLE 25              KEY REAGENTS AND KITS AVAILABLE IN MARKET               121

TABLE 26              MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION,

2023–2030 (USD MILLION)            122

TABLE 27              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY, 2023–2030 (USD MILLION)               122

TABLE 28              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            122

TABLE 29              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            123

TABLE 30              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            123

TABLE 31              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  123

TABLE 32              KEY INSTRUMENTS AVAILABLE IN MARKET                 125

TABLE 33              MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,

2023–2030 (USD MILLION)            125

TABLE 34              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 35              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            126

TABLE 36              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            127

TABLE 37              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            127

TABLE 38              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  127

TABLE 39              KEY SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE     128

TABLE 40              MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION,  2023–2030 (USD MILLION)                 129

TABLE 41              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE,  BY COUNTRY, 2023–2030 (USD MILLION) 129

TABLE 42              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            129

TABLE 43              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            130

TABLE 44              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            130

TABLE 45              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  130

TABLE 46              MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)                132

TABLE 47              KEY LABORATORY TESTING INSTRUMENTS AVAILABLE IN MARKET 133

TABLE 48              MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION,

2023–2030 (USD MILLION)            133

TABLE 49              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 50              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            134

TABLE 51              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            135

TABLE 52              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            135

TABLE 53              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            135

TABLE 54              KEY POC TESTING PRODUCTS AVAILABLE IN MARKET               137

TABLE 55              MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION,

2023–2030 (USD MILLION)            137

TABLE 56              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS,

BY COUNTRY, 2023–2030 (USD MILLION)               137

TABLE 57              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            138

TABLE 58              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            138

TABLE 59              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            139

TABLE 60              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            139

TABLE 61              MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            141

TABLE 62              KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET             142

TABLE 63              MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA,

BY REGION, 2023–2030 (USD MILLION)   143

TABLE 64              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2023–2030 (USD MILLION)            143

TABLE 65              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  144

TABLE 66              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  144

TABLE 67              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  145

TABLE 68              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  145

TABLE 69              KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET 146

TABLE 70              MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION,

2023–2030 (USD MILLION)            146

TABLE 71              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY,  2023–2030 (USD MILLION)                 146

TABLE 72              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION,  2023–2030 (USD MILLION)                 147

TABLE 73              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR URINE,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            147

TABLE 74              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            148

TABLE 75              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            148

TABLE 76              OTHER SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET 149

TABLE 77              MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION,  2023–2030 (USD MILLION)                 149

TABLE 78              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES,  BY COUNTRY, 2023–2030 (USD MILLION) 150

TABLE 79              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            150

TABLE 80              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            151

TABLE 81              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            151

TABLE 82              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  151

TABLE 83              MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            153

TABLE 84              KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE IN MARKET 155

TABLE 85              MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,

BY REGION, 2023–2030 (USD MILLION)   155

TABLE 86              MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        156

TABLE 87              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  156

TABLE 88              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            156

TABLE 89              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  157

TABLE 90              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  157

TABLE 91              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            157

TABLE 92              KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE IN MARKET               158

TABLE 93              MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)   159

TABLE 94              MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            159

TABLE 95              NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 159

TABLE 96              EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            160

TABLE 97              ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            160

TABLE 98              LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            161

TABLE 99              MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            161

TABLE 100            KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE IN MARKET 162

TABLE 101            MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)            162

TABLE 102            MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)               163

TABLE 103            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 163

TABLE 104            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  163

TABLE 105            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 164

TABLE 106            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            164

TABLE 107            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            164

TABLE 108            KEY IN SITU HYBRIDIZATION PRODUCTS AVAILABLE IN MARKET 165

TABLE 109            MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION,  2023–2030 (USD MILLION)                 166

TABLE 110            MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            166

TABLE 111            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 166

TABLE 112            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            167

TABLE 113            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            167

TABLE 114            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            168

TABLE 115            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  168

TABLE 116            KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET 169

TABLE 117            MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION,

2023–2030 (USD MILLION)            169

TABLE 118            MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            170

TABLE 119            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS,  BY COUNTRY, 2023–2030 (USD MILLION) 170

TABLE 120            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            170

TABLE 121            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            171

TABLE 122            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            171

TABLE 123            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  171

TABLE 124            MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2023–2030 (USD MILLION)            173

TABLE 125            MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 173

TABLE 126            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY, 2023–2030 (USD MILLION)       173

TABLE 127            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            174

TABLE 128            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            174

TABLE 129            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            175

TABLE 130            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  175

TABLE 131            MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              177

TABLE 132            KEY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        178

TABLE 133            MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,

BY REGION, 2023–2030 (USD MILLION)   179

TABLE 134            MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,

BY TYPE, 2023–2030 (USD MILLION)         179

TABLE 135            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)     179

TABLE 136            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  180

TABLE 137            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  180

TABLE 138            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  181

TABLE 139            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            181

TABLE 140            MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,

BY REGION, 2023–2030 (USD MILLION)   182

TABLE 141            MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,

BY TYPE, 2023–2030 (USD MILLION)         182

TABLE 142            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     183

TABLE 143            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  183

TABLE 144            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  184

TABLE 145            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  184

TABLE 146            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 184

TABLE 147            KEY CT/NG MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        185

TABLE 148            MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY REGION,

2023–2030 (USD MILLION)            186

TABLE 149            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY,  2023–2030 (USD MILLION)                 186

TABLE 150            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION,  2023–2030 (USD MILLION)                 186

TABLE 151            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET CT/NG, BY COUNTRY/REGION,  2023–2030 (USD MILLION)            187

TABLE 152            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            187

TABLE 153            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            187

TABLE 154            KEY HIV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 188

TABLE 155            MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY REGION,

2023–2030 (USD MILLION)            189

TABLE 156            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY,  2023–2030 (USD MILLION)                 189

TABLE 157            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION,  2023–2030 (USD MILLION)                 189

TABLE 158            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HIV, BY COUNTRY/REGION,  2023–2030 (USD MILLION)            190

TABLE 159            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            190

TABLE 160            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            190

TABLE 161            KEY HPV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET 191

TABLE 162            MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY REGION,

2023–2030 (USD MILLION)            192

TABLE 163            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY,  2023–2030 (USD MILLION)                 192

TABLE 164            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION,  2023–2030 (USD MILLION)                 192

TABLE 165            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HPV, BY COUNTRY/REGION,  2023–2030 (USD MILLION)            193

TABLE 166            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            193

TABLE 167            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)          193

TABLE 168            KEY SYPHILIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        194

TABLE 169            MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION,

2023–2030 (USD MILLION)            195

TABLE 170            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 171            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            195

TABLE 172            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            196

TABLE 173            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            196

TABLE 174            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            196

TABLE 175            OTHER SEXUALLY TRANSMITTED DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET                 197

TABLE 176            MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES,  BY REGION, 2023–2030 (USD MILLION)            198

TABLE 177            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     198

TABLE 178            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  198

TABLE 179            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  199

TABLE 180            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  199

TABLE 181            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            199

TABLE 182            KEY HEPATITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        200

TABLE 183            MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION,

2023–2030 (USD MILLION)            201

TABLE 184            MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            201

TABLE 185            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY, 2023–2030 (USD MILLION)               201

TABLE 186            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            202

TABLE 187            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            202

TABLE 188            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            203

TABLE 189            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            203

TABLE 190            MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION,

2023–2030 (USD MILLION)            204

TABLE 191            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY, 2023–2030 (USD MILLION)               204

TABLE 192            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            205

TABLE 193            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            205

TABLE 194            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            206

TABLE 195            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            206

TABLE 196            MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION,

2023–2030 (USD MILLION)            207

TABLE 197            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY, 2023–2030 (USD MILLION)               207

TABLE 198            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            208

TABLE 199            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            208

TABLE 200            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)          209

TABLE 201            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            209

TABLE 202            MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION)            210

TABLE 203            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       210

TABLE 204            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            211

TABLE 205            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  211

TABLE 206            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  212

TABLE 207            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  212

TABLE 208            MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION,  2023–2030 (USD MILLION)            213

TABLE 209            MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY TYPE,  2023–2030 (USD MILLION)                 213

TABLE 210            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES,  BY COUNTRY, 2023–2030 (USD MILLION)       214

TABLE 211            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            214

TABLE 212            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            215

TABLE 213            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            215

TABLE 214            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  215

TABLE 215            KEY TUBERCULOSIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        216

TABLE 216            MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION,

2023–2030 (USD MILLION)            217

TABLE 217            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS,

BY COUNTRY, 2023–2030 (USD MILLION)               217

TABLE 218            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            217

TABLE 219            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            218

TABLE 220            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)          218

TABLE 221            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  218

TABLE 222            GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES,

2023–2030 (MILLIONS)    219

TABLE 223            KEY INFLUENZA MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        219

TABLE 224            MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION,

2023–2030 (USD MILLION)            220

TABLE 225            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY, 2023–2030 (USD MILLION)               220

TABLE 226            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            220

TABLE 227            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            221

TABLE 228            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            221

TABLE 229            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            221

TABLE 230            KEY PHARYNGITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        222

TABLE 231            MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY REGION,

2023–2030 (USD MILLION)            223

TABLE 232            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS,

BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 233            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)            223

TABLE 234            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            224

TABLE 235            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            224

TABLE 236            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  224

TABLE 237            OTHER RESPIRATORY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET            225

TABLE 238            MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)       226

TABLE 239            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)     226

TABLE 240            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  226

TABLE 241            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  227

TABLE 242            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  227

TABLE 243            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION,

2023–2030 (USD MILLION)            227

TABLE 244            KEY HOSPITAL-ACQUIRED INFECTION-BASED MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET                 228

TABLE 245            MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS,

BY REGION, 2023–2030 (USD MILLION)   229

TABLE 246            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)            229

TABLE 247            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  229

TABLE 248            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HOSPITAL-ACQUIRED INFECTIONS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  230

TABLE 249            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  230

TABLE 250            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)                 230

TABLE 251            KEY VECTOR-BORNE DISEASES DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET        231

TABLE 252            MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY REGION,  2023–2030 (USD MILLION)            232

TABLE 253            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       232

TABLE 254            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            232

TABLE 255            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET VECTOR-BORNE DISEASES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            233

TABLE 256            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  233

TABLE 257            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  233

TABLE 258            GLOBAL CASES OF ACTIVE SYPHILIS IN AGE GROUP FROM 15 TO 49 YEARS,  2016–2022 (THOUSANDS)                 234

TABLE 259            OTHER INFECTIOUS DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET            235

TABLE 260            MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES,

BY REGION, 2023–2030 (USD MILLION)   235

TABLE 261            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            236

TABLE 262            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            236

TABLE 263            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  237

TABLE 264            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  237

TABLE 265            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  237

TABLE 266            KEY ONCOLOGY TESTING PRODUCTS AVAILABLE IN MARKET 239

TABLE 267            MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION,

2023–2030 (USD MILLION)            239

TABLE 268            MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,

2023–2030 (USD MILLION)            240

TABLE 269            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,  BY COUNTRY, 2023–2030 (USD MILLION) 240

TABLE 270            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            240

TABLE 271            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            241

TABLE 272            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            241

TABLE 273            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  241

TABLE 274            BREAST CANCER INCIDENCE, BY REGION, 2022 VS. 2030 242

TABLE 275            MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION,

2023–2030 (USD MILLION)            243

TABLE 276            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER,

BY COUNTRY, 2023–2030 (USD MILLION)               243

TABLE 277            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            243

TABLE 278            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            244

TABLE 279            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)          244

TABLE 280            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  244

TABLE 281            COLORECTAL CANCER INCIDENCE, BY REGION, 2022 VS. 2030       245

TABLE 282            MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION,  2023–2030 (USD MILLION)                 245

TABLE 283            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER,  BY COUNTRY, 2023–2030 (USD MILLION) 246

TABLE 284            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            246

TABLE 285            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            246

TABLE 286            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            247

TABLE 287            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  247

TABLE 288            LUNG CANCER INCIDENCE, BY REGION, 2022 VS. 2030        248

TABLE 289            MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION,

2023–2030 (USD MILLION)            248

TABLE 290            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER,

BY COUNTRY, 2023–2030 (USD MILLION)               248

TABLE 291            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            249

TABLE 292            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            249

TABLE 293            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            250

TABLE 294            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  250

TABLE 295            PROSTATE CANCER INCIDENCE, BY REGION, 2022 VS. 2030       251

TABLE 296            MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION,

2023–2030 (USD MILLION)            251

TABLE 297            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER,  BY COUNTRY, 2023–2030 (USD MILLION) 251

TABLE 298            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            252

TABLE 299            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            252

TABLE 300            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            253

TABLE 301            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  253

TABLE 302            GLOBAL INCIDENCE OF OTHER CANCER TYPES, 2022 VS. 2030       253

TABLE 303            MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY REGION,  2023–2030 (USD MILLION)                 254

TABLE 304            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES,  BY COUNTRY, 2023–2030 (USD MILLION) 254

TABLE 305            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            255

TABLE 306            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            255

TABLE 307            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            256

TABLE 308            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  256

TABLE 309            KEY GENETIC TESTING PRODUCTS AVAILABLE IN MARKET         257

TABLE 310            MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION,

2023–2030 (USD MILLION)            257

TABLE 311            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 312            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            258

TABLE 313            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            258

TABLE 314            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            259

TABLE 315            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  259

TABLE 316            MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION,  2023–2030 (USD MILLION)                 260

TABLE 317            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2023–2030 (USD MILLION) 260

TABLE 318            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            260

TABLE 319            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            261

TABLE 320            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            261

TABLE 321            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     261

TABLE 322            MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 263

TABLE 323            KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET 264

TABLE 324            MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY REGION,

2023–2030 (USD MILLION)            264

TABLE 325            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING,  BY COUNTRY, 2023–2030 (USD MILLION) 265

TABLE 326            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            265

TABLE 327            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            266

TABLE 328            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            266

TABLE 329            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  266

TABLE 330            KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET 267

TABLE 331            MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY REGION,  2023–2030 (USD MILLION)                 268

TABLE 332            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING,  BY COUNTRY, 2023–2030 (USD MILLION) 268

TABLE 333            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            269

TABLE 334            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            269

TABLE 335            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            270

TABLE 336            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  270

TABLE 337            MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,

2023–2030 (USD MILLION)            272

TABLE 338            KEY DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET               273

TABLE 339            MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY REGION,

2023–2030 (USD MILLION)            273

TABLE 340            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC,

BY COUNTRY, 2023–2030 (USD MILLION)               273

TABLE 341            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            274

TABLE 342            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            274

TABLE 343            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            275

TABLE 344            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  275

TABLE 345            KEY SCREENING PRODUCTS AVAILABLE IN MARKET               276

TABLE 346            MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY REGION,

2023–2030 (USD MILLION)            276

TABLE 347            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY, 2023–2030 (USD MILLION)               276

TABLE 348            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            277

TABLE 349            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            277

TABLE 350            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            278

TABLE 351            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            278

TABLE 352            MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)                280

TABLE 353            MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)            281

TABLE 354            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)            281

TABLE 355            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            282

TABLE 356            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  282

TABLE 357            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  283

TABLE 358            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  283

TABLE 359            MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION,  2023–2030 (USD MILLION)                 284

TABLE 360            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            285

TABLE 361            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            285

TABLE 362            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            285

TABLE 363            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)            286

TABLE 364            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)  286

TABLE 365            MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,

2023–2030 (USD MILLION)            287

TABLE 366            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,  BY COUNTRY, 2023–2030 (USD MILLION) 287

TABLE 367            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            288

TABLE 368            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            288

TABLE 369            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY/REGION, 2023–2030 (USD MILLION)            289

TABLE 370            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,  BY COUNTRY/REGION, 2023–2030 (USD MILLION)  289

TABLE 371            PROJECTED CANCER CASES, BY COUNTRY, 2030                 291

TABLE 372            MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)          292

TABLE 373            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            294

TABLE 374            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 295

TABLE 375            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            295

TABLE 376            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            295

TABLE 377            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            296

TABLE 378            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            296

TABLE 379            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            297

TABLE 380            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 297

TABLE 381            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            298

TABLE 382            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            298

TABLE 383            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)            298

TABLE 384            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)          299

TABLE 385            NORTH AMERICA: MACROECONOMIC INDICATORS      299

TABLE 386            US: CANCER CASES AND MORTALITY, BY CANCER TYPE, 2022 VS. 2030        300

TABLE 387            US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            301

TABLE 388            US: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            301

TABLE 389            US: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            301

TABLE 390            US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            302

TABLE 391            US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            302

TABLE 392            US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION)            303

TABLE 393            US: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            303

TABLE 394            US: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION)            303

TABLE 395            US: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 304

TABLE 396            US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 304

TABLE 397            US: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            304

TABLE 398            CANADA: PROJECTED CANCER CASES, BY TYPE, 2030        305

TABLE 399            CANADA: FIVE COMMON CANCER TYPES AND DEATH PERCENTAGE    305

TABLE 400            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            306

TABLE 401            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            307

TABLE 402            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            307

TABLE 403            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            307

TABLE 404            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            308

TABLE 405            CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 308

TABLE 406            CANADA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 407            CANADA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 309

TABLE 408            CANADA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 309

TABLE 409            CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 309

TABLE 410            CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            310

TABLE 411            EUROPE: MACROECONOMIC INDICATORS                 311

TABLE 412            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            311

TABLE 413            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            312

TABLE 414            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            312

TABLE 415            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            312

TABLE 416            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            313

TABLE 417            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            313

TABLE 418            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 314

TABLE 419            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            314

TABLE 420            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 315

TABLE 421            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 315

TABLE 422            EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 315

TABLE 423            EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            316

TABLE 424            GERMANY: PROJECTED CANCER CASES, BY TYPE, 2030           316

TABLE 425            GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            317

TABLE 426            GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            318

TABLE 427            GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            318

TABLE 428            GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            318

TABLE 429            GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            319

TABLE 430            GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            319

TABLE 431            GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            319

TABLE 432            GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            320

TABLE 433            GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            320

TABLE 434            GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         320

TABLE 435            GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            321

TABLE 436            UK: PROJECTED CANCER CASES, BY TYPE, 2030                 322

TABLE 437            UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            323

TABLE 438            UK: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)          323

TABLE 439            UK: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            323

TABLE 440            UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            324

TABLE 441            UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            324

TABLE 442            UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION)            325

TABLE 443            UK: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            325

TABLE 444            UK: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION)            326

TABLE 445            UK: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 326

TABLE 446            UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 326

TABLE 447            UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            327

TABLE 448            FRANCE: PROJECTED CANCER CASES, BY TYPE, 2030        328

TABLE 449            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            328

TABLE 450            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            328

TABLE 451            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            329

TABLE 452            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            329

TABLE 453            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            329

TABLE 454            FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 330

TABLE 455            FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            330

TABLE 456            FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 330

TABLE 457            FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 331

TABLE 458            FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 331

TABLE 459            FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            331

TABLE 460            ITALY: PROJECTED CANCER CASES, BY TYPE, 2030        333

TABLE 461            ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            333

TABLE 462            ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            333

TABLE 463            ITALY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            334

TABLE 464            ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            334

TABLE 465            ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            334

TABLE 466            ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION) 335

TABLE 467            ITALY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            335

TABLE 468            ITALY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 335

TABLE 469            ITALY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 336

TABLE 470            ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 336

TABLE 471            ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            336

TABLE 472            SPAIN: PROJECTED CANCER CASES, BY TYPE, 2030        337

TABLE 473            SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            338

TABLE 474            SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            338

TABLE 475            SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            338

TABLE 476            SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            339

TABLE 477            SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            339

TABLE 478            SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION) 340

TABLE 479            SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            340

TABLE 480            SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 341

TABLE 481            SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 341

TABLE 482            SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 341

TABLE 483            SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            342

TABLE 484            RUSSIA: PROJECTED CANCER CASES, BY TYPE, 2030        343

TABLE 485            RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            343

TABLE 486            RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            343

TABLE 487            RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            344

TABLE 488            RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            344

TABLE 489            RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            344

TABLE 490            RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 345

TABLE 491            RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            345

TABLE 492            RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 346

TABLE 493            RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 346

TABLE 494            RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 346

TABLE 495            RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            347

TABLE 496            SWITZERLAND: PROJECTED CANCER CASES, BY TYPE, 2030           348

TABLE 497            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 348

TABLE 498            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            348

TABLE 499            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            349

TABLE 500            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            349

TABLE 501            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            349

TABLE 502            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            350

TABLE 503            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 350

TABLE 504            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            351

TABLE 505            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            351

TABLE 506            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         351

TABLE 507            SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            352

TABLE 508            REST OF EUROPE: PROJECTED CANCER CASES, BY COUNTRY, 2030           352

TABLE 509            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 353

TABLE 510            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            353

TABLE 511            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            353

TABLE 512            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            354

TABLE 513            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            354

TABLE 514            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            355

TABLE 515            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 355

TABLE 516            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            356

TABLE 517            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            356

TABLE 518            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2023–2030 (USD MILLION)            356

TABLE 519            REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            357

TABLE 520            ASIA PACIFIC: MACROECONOMIC INDICATORS                 358

TABLE 521            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            359

TABLE 522            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 359

TABLE 523            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            360

TABLE 524            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            360

TABLE 525            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            360

TABLE 526            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            361

TABLE 527            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            361

TABLE 528            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 361

TABLE 529            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            362

TABLE 530            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            362

TABLE 531            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         362

TABLE 532            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            363

TABLE 533            CHINA: PROJECTED CANCER CASES, BY TYPE, 2030        364

TABLE 534            CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            364

TABLE 535            CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            364

TABLE 536            CHINA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            365

TABLE 537            CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            365

TABLE 538            CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            365

TABLE 539            CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION) 366

TABLE 540            CHINA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            366

TABLE 541            CHINA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 366

TABLE 542            CHINA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 367

TABLE 543            CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 367

TABLE 544            CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            367

TABLE 545            JAPAN: PROJECTED CANCER CASES, BY TYPE, 2030        369

TABLE 546            JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            369

TABLE 547            JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            369

TABLE 548            JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            370

TABLE 549            JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            370

TABLE 550            JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            370

TABLE 551            JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION) 371

TABLE 552            JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            371

TABLE 553            JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 371

TABLE 554            JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 372

TABLE 555            JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 372

TABLE 556            JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            372

TABLE 557            INDIA: PROJECTED CANCER CASES, BY TYPE, 2030        374

TABLE 558            INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            374

TABLE 559            INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            375

TABLE 560            INDIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            375

TABLE 561            INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            375

TABLE 562            INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            376

TABLE 563            INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION) 376

TABLE 564            INDIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            376

TABLE 565            INDIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 377

TABLE 566            INDIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 377

TABLE 567            INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 377

TABLE 568            INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            378

TABLE 569            AUSTRALIA: PROJECTED CANCER CASES, BY TYPE, 2030           379

TABLE 570            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            379

TABLE 571            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            379

TABLE 572            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            380

TABLE 573            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            380

TABLE 574            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            380

TABLE 575            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            381

TABLE 576            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            381

TABLE 577            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            382

TABLE 578            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            382

TABLE 579            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         382

TABLE 580            AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            383

TABLE 581            SOUTH KOREA: PROJECTED CANCER CASES, BY TYPE, 2030           384

TABLE 582            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 384

TABLE 583            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            384

TABLE 584            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            385

TABLE 585            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            385

TABLE 586            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            385

TABLE 587            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            386

TABLE 588            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 386

TABLE 589            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            387

TABLE 590            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            387

TABLE 591            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         387

TABLE 592            SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            388

TABLE 593            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 389

TABLE 594            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            389

TABLE 595            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            389

TABLE 596            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            390

TABLE 597            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,  2023–2030 (USD MILLION)            390

TABLE 598            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)          391

TABLE 599            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         391

TABLE 600            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)   392

TABLE 601            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)   392

TABLE 602            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2023–2030 (USD MILLION)            392

TABLE 603            REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            393

TABLE 604            LATIN AMERICA: MACROECONOMIC INDICATORS      394

TABLE 605            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            394

TABLE 606            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 395

TABLE 607            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            395

TABLE 608            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            395

TABLE 609            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            396

TABLE 610            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            396

TABLE 611            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            397

TABLE 612            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 397

TABLE 613            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            398

TABLE 614            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            398

TABLE 615            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         398

TABLE 616            LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            399

TABLE 617            BRAZIL: PROJECTED CANCER CASES, BY TYPE, 2030        400

TABLE 618            BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            400

TABLE 619            BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            400

TABLE 620            BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            401

TABLE 621            BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            401

TABLE 622            BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            401

TABLE 623            BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION) 402

TABLE 624            BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            402

TABLE 625            BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 403

TABLE 626            BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 403

TABLE 627            BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 403

TABLE 628            BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            404

TABLE 629            MEXICO: PROJECTED CANCER CASES, BY TYPE, 2030        405

TABLE 630            MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            405

TABLE 631            MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            405

TABLE 632            MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            406

TABLE 633            MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            406

TABLE 634            MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            406

TABLE 635            MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION) 407

TABLE 636            MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            407

TABLE 637            MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION) 408

TABLE 638            MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION) 408

TABLE 639            MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 408

TABLE 640            MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            409

TABLE 641            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 410

TABLE 642            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,  2023–2030 (USD MILLION)            410

TABLE 643            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            410

TABLE 644            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            411

TABLE 645            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,  2023–2030 (USD MILLION)            411

TABLE 646            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)          412

TABLE 647            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         412

TABLE 648            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)   413

TABLE 649            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)   413

TABLE 650            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)            413

TABLE 651            REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,  2023–2030 (USD MILLION)            414

TABLE 652            MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS      415

TABLE 653            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,  2023–2030 (USD MILLION)            415

TABLE 654            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 416

TABLE 655            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,  2023–2030 (USD MILLION)            416

TABLE 656            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,  2023–2030 (USD MILLION)            416

TABLE 657            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,  2023–2030 (USD MILLION)            417

TABLE 658            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,  2023–2030 (USD MILLION)            417

TABLE 659            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)          418

TABLE 660            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,

BY TYPE, 2023–2030 (USD MILLION)         418

TABLE 661            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)   419

TABLE 662            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)   419

TABLE 663            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)            419

TABLE 664            MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,  2023–2030 (USD MILLION)            420

TABLE 665            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023–2030 (USD MILLION)                 421

TABLE 666            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            421

TABLE 667            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            421

TABLE 668            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            422

TABLE 669            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            422

TABLE 670            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)            423

TABLE 671            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,  2023–2030 (USD MILLION)                 423

TABLE 672            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)            424

TABLE 673            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)            424

TABLE 674            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,

BY TYPE, 2023–2030 (USD MILLION)         424

TABLE 675            SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            425

TABLE 676            UAE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            426

TABLE 677            UAE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2023–2030 (USD MILLION)            426

TABLE 678            UAE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2023–2030 (USD MILLION)            426

TABLE 679            UAE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            427

TABLE 680            UAE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            427

TABLE 681            UAE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2023–2030 (USD MILLION)            428

TABLE 682            UAE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE,

2023–2030 (USD MILLION)            428

TABLE 683            UAE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES,  BY TYPE, 2023–2030 (USD MILLION)            429

TABLE 684            UAE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES,  BY TYPE, 2023–2030 (USD MILLION) 429

TABLE 685            UAE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE,  2023–2030 (USD MILLION)                 429

TABLE 686            UAE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2023–2030 (USD MILLION)            430

TABLE 687            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        431

TABLE 688            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)            431

TABLE 689            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)            431

TABLE 690            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     432

TABLE 691            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       432

TABLE 692            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)          433

TABLE 693            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,  BY TYPE, 2023–2030 (USD MILLION) 433

TABLE 694            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)   434

TABLE 695            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)   434

TABLE 696            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)            434

TABLE 697            REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET,

BY END USER, 2023–2030 (USD MILLION)               435

TABLE 698            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS,

JANUARY 2021−JULY 2025             436

TABLE 699            MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION           439

TABLE 700            MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT       443

TABLE 701            MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT           444

TABLE 702            MOLECULAR DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT            444

TABLE 703            MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT         445

TABLE 704            MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES             447

TABLE 705            MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)                 447

TABLE 706            MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)                 448

TABLE 707            MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025  450

TABLE 708            MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JULY 2025               451

TABLE 709            MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021– JULY 2025 452

TABLE 710            DANAHER CORPORATION: COMPANY OVERVIEW          453

TABLE 711            DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED               454

TABLE 712            DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 456

TABLE 713            DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2025  457

TABLE 714            DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025               458

TABLE 715            F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW          460

TABLE 716            F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED               461

TABLE 717            F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES AND APPROVALS,  JANUARY 2021–JULY 2025  463

TABLE 718            F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–JULY 2025               465

TABLE 719            ILLUMINA, INC.: COMPANY OVERVIEW 467

TABLE 720            ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED             468

TABLE 721            ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2025               469

TABLE 722            ILLUMINA, INC.: DEALS, JANUARY 2021– JULY 2025        470

TABLE 723            ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–JULY 2025             471

TABLE 724            HOLOGIC, INC.: COMPANY OVERVIEW  473

TABLE 725            HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED             474

TABLE 726            HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2025               475

TABLE 727            HOLOGIC, INC.: DEALS, JANUARY 2021– JULY 2025        476

TABLE 728            BIOMÉRIEUX: COMPANY OVERVIEW      478

TABLE 729            BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED                 479

TABLE 730            BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2025               481

TABLE 731            BIOMÉRIEUX: DEALS, JANUARY 2021– JULY 2025                 482

TABLE 732            ABBOTT LABORATORIES: COMPANY OVERVIEW          484

TABLE 733            ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED               485

TABLE 734            ABBOTT LABORATORIES: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025 487

TABLE 735            ABBOTT LABORATORIES: DEALS, JANUARY 2021– JULY 2025 488

TABLE 736            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          489

TABLE 737            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED               490

TABLE 738            THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS,  JANUARY 2021–JULY 2025  491

TABLE 739            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021– JULY 2025              492

TABLE 740            QIAGEN N.V.: COMPANY OVERVIEW       493

TABLE 741            QIAGEN N.V.: PRODUCTS/SERVICES OFFERED                 494

TABLE 742            QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2025               496

TABLE 743            QIAGEN N.V.: DEALS, JANUARY 2021– JULY 2025                 498

TABLE 744            QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JULY 2025        499

TABLE 745            REVVITY, INC.: COMPANY OVERVIEW    500

TABLE 746            REVVITY, INC.: PRODUCTS/SERVICES OFFERED                 501

TABLE 747            MYRIAD GENETICS, INC.: COMPANY OVERVIEW                 502

TABLE 748            MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED             503

TABLE 749            MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS,  JANUARY 2021–JULY 2025                 504

TABLE 750            MYRIAD GENETICS, INC.: DEALS, JANUARY 2021- JULY 2025             504

TABLE 751            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          507

TABLE 752            SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED               508

TABLE 753            SIEMENS HEALTHINEERS AG: PRODUCT/SERVICE LAUNCHES AND APPROVALS,  JANUARY 2021–JULY 2025  509

TABLE 754            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– JULY 2025 509

TABLE 755            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021– JULY 2025              510

TABLE 756            BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW   511

TABLE 757            GRIFOLS, S.A.: COMPANY OVERVIEW      512

TABLE 758            QUIDELORTHO CORPORATION: COMPANY OVERVIEW          513

TABLE 759            DIASORIN S.P.A.: COMPANY OVERVIEW 514

TABLE 760            EXACT SCIENCES CORPORATION: COMPANY OVERVIEW          516

TABLE 761            GENETIC SIGNATURES: COMPANY OVERVIEW                 517

TABLE 762            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          518

TABLE 763            MDXHEALTH: COMPANY OVERVIEW      519

TABLE 764            BIOCARTIS: COMPANY OVERVIEW          520

TABLE 765            MEDIGEN BIOTECHNOLOGY CORP.: COMPANY OVERVIEW          521

TABLE 766            VELA DIAGNOSTICS: COMPANY OVERVIEW                 522

TABLE 767            AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW          523

TABLE 768            BRUKER CORPORATION (ELITECHGROUP): COMPANY OVERVIEW   524

TABLE 769            MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW          526

TABLE 770            GENEOMBIOTECHNOLOGIES: COMPANY OVERVIEW          527

TABLE 771            SAVYON DIAGNOSTICS: COMPANY OVERVIEW                 528

TABLE 772            UNIOGEN OY: COMPANY OVERVIEW      529

LIST OF FIGURES

FIGURE 1              RESEARCH DESIGN METHODOLOGY      53

FIGURE 2              KEY PRIMARY SOURCES                56

FIGURE 3              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS            59

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     59

FIGURE 5              BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH              60

FIGURE 6              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 61

FIGURE 7              MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH          62

FIGURE 8              DATA TRIANGULATION METHODOLOGY                 63

FIGURE 9              MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS           64

FIGURE 10            MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2025 VS. 2030 (USD MILLION)      66

FIGURE 11            MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,

2025 VS. 2030 (USD MILLION)      67

FIGURE 12            MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,

2025 VS. 2030 (USD MILLION)      67

FIGURE 13            MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,

2025 VS. 2030 (USD MILLION)      68

FIGURE 14            MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,

2025 VS. 2030 (USD MILLION)      69

FIGURE 15            MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE,

2025 VS. 2030 (USD MILLION)      70

FIGURE 16            MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION,

2025 VS. 2030 (USD MILLION)      70

FIGURE 17            MOLECULAR DIAGNOSTICS MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      71

FIGURE 18            MOLECULAR DIAGNOSTICS MARKET, BY REGION,  2025 VS. 2030 (USD MILLION)                 72

FIGURE 19            INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO

DRIVE MARKET 73

FIGURE 20            REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    73

FIGURE 21            LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD       74

FIGURE 22            BLOOD, SERUM, AND PLASMA SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD                 74

FIGURE 23            POLYMERASE CHAIN REACTION SEGMENT TO ACHIEVE LARGEST SHARE DURING FORECAST PERIOD 75

FIGURE 24            INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD                75

FIGURE 25            MULTIPLEX TESTING SEGMENT TO ACCOUNT FOR SIGNIFICANT SHARE DURING FORECAST PERIOD  76

FIGURE 26            DIAGNOSTIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    76

FIGURE 27            DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET IN 2030   77

FIGURE 28            NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD        77

FIGURE 29            MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          78

FIGURE 30            INCIDENCE OF HIV, BY REGION, 2024     80

FIGURE 31            PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES, JANUARY 2015–DECEMBER 2024                90

FIGURE 32            MOLECULAR DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS              92

FIGURE 33            MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS              94

FIGURE 34            MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS  96

FIGURE 35            MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS           97

FIGURE 36            MOLECULAR DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 109

FIGURE 37            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE         109

FIGURE 38            KEY BUYING CRITERIA, BY PRODUCT & SERVICE                 110

FIGURE 39            NUMBER OF DEALS & TOTAL FUNDING, 2021–2025        111

FIGURE 40            MOLECULAR DIAGNOSTICS MARKET: KEY USE CASES   113

FIGURE 41            NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT       294

FIGURE 42            ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT       358

FIGURE 43            REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 438

FIGURE 44            MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024        439

FIGURE 45            MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       442

FIGURE 46            MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT 443

FIGURE 47            MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 446

FIGURE 48            EV/EBITDA OF KEY VENDORS   448

FIGURE 49            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS      449

FIGURE 50            BRAND/PRODUCT COMPARISON FOR MOLECULAR DIAGNOSTIC INSTRUMENTS          450

FIGURE 51            DANAHER CORPORATION: COMPANY SNAPSHOT (2024)             454

FIGURE 52            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)             461

FIGURE 53            ILLUMINA, INC.: COMPANY SNAPSHOT (2024)                 468

FIGURE 54            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 474

FIGURE 55            BIOMÉRIEUX: COMPANY SNAPSHOT (2024)                 479

FIGURE 56            ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024)             485

FIGURE 57            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             490

FIGURE 58            QIAGEN N.V.: COMPANY SNAPSHOT (2024)                 494

FIGURE 59            REVVITY, INC.: COMPANY SNAPSHOT (2024)                 501

FIGURE 60            MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024)    503

FIGURE 61            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             508

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧